Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax and Exviera dasabuvir with and without ribavirin for 12 weeks led to SVR4 rates

Read the full 364 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE